
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher is attractive because its 1984 transformation and later portfolio reshaping have left it concentrated in higher-quality life sciences and diagnostics, where recurring consumables, instruments, and bioprocessing demand support durable growth. Its 3Q26 results reinforced that thesis, with $6.55B in revenue, 3.0% core growth, 29.0% adjusted operating margin, $2.11 adjusted EPS, and $1.6B of free cash flow, while bioprocessing orders grew mid-teens and diagnostics improved ex respiratory. The combination of a more conservative 4% to 5% 2027 core growth starting point, improving end markets, easing headwinds, and continued capital deployment through tuck-in acquisitions supports a positive long-term outlook.
Bears say
Danaher is facing a fundamentally weaker growth profile because 4Q26 core growth is expected to slow to about +3.0%, below the Street’s +5.2% estimate, while respiratory alone creates roughly a 150 bp drag and revenue is forecast near $400M versus about $500M in 4Q25. Its Life Sciences business has lagged, instrument demand continues to decline, bioprocess equipment recovery has not materialized, and Diagnostics still faces China headwinds even as the company’s ability to offset these issues through M&A has come into question after several recent acquisitions failed to meet expectations. Although adjusted operating margin is still expected to be about 29.5% in 4Q26 and YTD adjusted EPS stands at $6.11 with margin at 28.7%, the lack of a full-year margin outlook and risks from weaker biopharma spending, lower research funding, and hospital lab softness support a negative outlook.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Danaher (DHR) Forecast
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares